查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018599

韓特氏症治療市場：依治療方法、給藥途徑、患者年齡層和最終用戶分類－2026-2032年全球市場預測

Hunter Syndrome Treatment Market by Treatment Type, Route Of Administration, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年韓特氏症治療市場價值 12.7 億美元，預計到 2026 年將成長至 13.8 億美元，複合年成長率為 9.04%，到 2032 年將達到 23.3 億美元。

主要市場統計數據
基準年 2025 12.7億美元
預計年份：2026年 13.8億美元
預測年份 2032 23.3億美元
複合年成長率 (%) 9.04%

全面概述影響韓特氏症。

韓特氏症（黏多醣症II型）持續為藥物研發、臨床照護和醫療保健系統的相關人員帶來嚴峻的臨床、營運和策略挑戰。儘管分子生物學和載體工程的進步已將治療選擇拓展到傳統酵素替代療法之外，但持續改善中樞神經系統症狀和確保公平獲得治療仍然是亟待解決的優先事項。同時，不斷變化的法規結構和支付方的審查正在重新定義對證據的期望，要求更複雜的試驗設計和更充分的衛生經濟學論點。

治療方法策略的轉變、對證據的期望以及護理模式的轉變，正在推動韓特氏症創新和准入規劃的新時代。

韓特氏症的治療格局正在經歷一場變革，這主要得益於科學突破、監管進步以及相關人員期望的轉變。利用腺結合病毒載體和慢病毒構建體的基因治療平台正從前景可觀的臨床前階段邁向早期臨床概念驗證階段，促使人們重新思考長期以來以靜脈注射酶替代療法為主導的治療模式。同時，酵素工程、生產規模化以及替代給藥策略的改進正在擴大替代療法的臨床效用，並實現以患者為中心的給藥方案。

美國近期關稅措施對韓特氏症治療的供應鏈、籌資策略和成本風險管理的累積影響。

美國關稅調整及相關政策變化的前景正開始影響用於治療韓特氏症的進口治療性原料藥和成品生物製藥的供應鏈規劃、籌資策略和價格談判。依賴跨國採購病毒載體、關鍵原料藥或成品的製造商正面臨投入成本波動加劇和前置作業時間可能延長的困境。為此，許多研發公司和契約製造正在重新評估其生產能力的地理多元化，並與供應商協商簽訂更長期的契約，以穩定供應並確保臨床試驗按計劃進行。

透過基於細分的詳細分析，揭示治療方法、給藥途徑、年齡層和醫療保健服務環境如何影響臨床和商業策略。

一套精細的細分框架闡明如何根據不同的治療方法和患者情況，量身定做臨床策略、商業模式和醫療服務。根據治療類型，該領域包括酵素替代療法、基因療法、造血幹細胞移植和支持性治療。在酵素替代療法中，諸如艾杜硫酶及其生物相似藥或下一代類似物等產品，各自具有不同的臨床特徵和生產系統。另一方面，基因療法又分為腺結合病毒載體和慢病毒載體兩種途徑，每種途徑在安全性、持久性和生產方面都存在差異。造血幹細胞移植途徑包括同種異體移植和自體移植，每種途徑的移植物抗宿主疾病風險和基礎設施要求各不相同。支持治療仍然至關重要，通常包括營養支持、疼痛管理、物理治療和呼吸支持，這些措施全面支撐著旨在改善生活品質的干涉措施。

區域策略差異和營運因素決定了全球主要市場的監管路徑、進入模式和生產重點。

區域趨勢對監管路徑、報銷環境、製造地選擇和病患准入模式均有顯著影響。在美洲，罕見疾病護理網路的結構優勢、成熟的專科藥房管道以及集中化的支付方談判流程，為新治療方法的推廣既帶來了機會也構成了阻礙，尤其需要重視療效驗證和管理式准入協議。同時，歐洲、中東和非洲（EMEA）地區的監管環境和醫療財務狀況各不相同，既存在集中核准體系，也存在各國特定的定價和准入機制。這就需要針對不同地區制定個人化的證據包和差異化的上市策略。此外，區域基礎設施能力的差異也會影響複雜給藥途徑和先進治療物流的可行性。

以平台差異化、策略夥伴關係和實際服務模式為重點的競爭優勢分析，旨在推動韓特氏症治療的普及。

在韓特氏症治療領域，各公司之間的競爭格局更取決於平台差異化、臨床證據的深度以及供應鏈的韌性，而非簡單的產品線。推廣酵素替代療法候選藥物的機構正優先考慮提高給藥頻率、改善免疫抗原性原性以及降低生產成本，以在基因治療方法興起的浪潮中保持競爭力。基因療法研發公司正大力投資於載體最佳化、劑量範圍確定和長期安全性監測，以解決人們對療效持久性和脫靶效應的擔憂，同時也在建立專門的生產能力，以滿足複雜的生產需求。

為開發人員和相關人員制定可操作的策略重點，以加速臨床影響、確保支付方接受並加強罕見疾病治療的供應鏈韌性。

產業領導者應採取整合策略方針，將科學創新與切實可行的商業化和以病人為中心的准入模式結合。首先，他們應優先投資於能夠實證改善中樞神經系統（CNS）滲透性、永續性或安全性的平台技術，以滿足最迫切的未滿足需求並創造合理的差異化優勢。其次，他們應制定生產策略，平衡內部生產能力與策略外包，並融入地理分散化，以確保臨床專案和商業供應鏈的連續性，同時降低關稅和供應鏈風險。

採用穩健的多方法研究途徑，結合專家的直接訪談、系統性的文獻整合和多方相關人員的檢驗，以支持實際見解。

本執行摘要的分析基於多方面的研究途徑，該方法整合了關鍵相關人員的見解、對二手證據的嚴格審查以及定量三角驗證。主要研究包括對代謝神經病學和兒童神經病學專科臨床醫生、醫療系統藥劑師、供應鏈和生產專家以及患者權益倡導團體代表的訪談，以了解實際運營中的挑戰和未滿足的需求。二手研究包括對同行評審的臨床文獻、監管指導文件以及與治療方法、安全性訊號和臨床試驗終點相關的公開資料進行系統性審查。

整合策略挑戰和合作途徑，將科學進步轉化為永續的臨床效益和公平的患者獲取途徑。

韓特氏症治療創新的進展表明，治療環境將更加多元化，酵素替代療法、基因療法、根治性移植以及全面的支持性護理將並存。在此環境下取得成功取決於保持靈活性，以滿足患者和看護者的需求，同時兼顧科學成果、實際可行性以及支付方認可的價值。早期診斷和及時治療性介入能夠最大程度地提高臨床獲益，這也凸顯了持續投資於篩檢、多學科診療模式和長期療效評估的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：韓特氏症治療市場（依治療方法分類）

  • 酵素替代療法
    • 偶像硫酸酶
    • 碘代硫酸酶BETA
  • 基因治療
    • 腺結合病毒載體
    • 慢病毒載體
  • 造血幹細胞移植
    • 同種異體移植
    • 自體移植
  • 支持性護理
    • 營養支持
    • 疼痛管理
    • 物理治療
    • 呼吸系統護理

第9章：韓特氏症治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：依患者年齡層分類的韓特氏症治療市場

  • 成人版
    • 中年
    • 老年人
    • 青年人
  • 兒童
    • 青年
    • 兒童
    • 嬰兒
    • 嬰兒

第11章韓特氏症治療市場：依最終用戶分類

  • 門診手術中心
  • 家庭靜脈輸液治療
  • 醫院
  • 專科診所

第12章韓特氏症治療市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章韓特氏症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章韓特氏症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國韓特氏症治療市場

第16章：中國韓特氏症治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott
  • ArmaGen, Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Denali Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Green Cross Corporation
  • GSK Plc.
  • Inventiva SA
  • JCR Pharmaceuticals Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic
  • Regenxbio Inc.
  • Sangamo Therapeutics, Inc.
  • Stryker Corporation
  • Takeda Pharmaceutical Company Limited
  • Zimmer Biomet
Product Code: MRR-B9334AD6C5BB

The Hunter Syndrome Treatment Market was valued at USD 1.27 billion in 2025 and is projected to grow to USD 1.38 billion in 2026, with a CAGR of 9.04%, reaching USD 2.33 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.27 billion
Estimated Year [2026] USD 1.38 billion
Forecast Year [2032] USD 2.33 billion
CAGR (%) 9.04%

Comprehensive orientation to the clinical, regulatory, and operational realities shaping therapeutic innovation and care pathways for Hunter syndrome

Hunter syndrome (mucopolysaccharidosis II) continues to present profound clinical, operational, and strategic challenges for stakeholders across drug development, clinical care, and health systems. Advances in molecular biology and vector engineering have expanded the universe of therapeutic options beyond conventional enzyme replacement therapy, yet durable correction of central nervous system manifestations and equitable access remain unresolved priorities. Meanwhile, evolving regulatory frameworks and payer scrutiny are reshaping evidence expectations, necessitating more sophisticated trial designs and health economic arguments.

Clinicians are balancing symptomatic management with disease-modifying approaches while caregivers and patient advocacy groups increasingly influence trial design and access pathways. Concurrently, manufacturing complexities for biologics and gene therapies, including viral vector production and cold-chain logistics, are creating new operational bottlenecks and cost pressures. As a result, developers, payers, and providers must integrate clinical insights with practical deployment strategies to translate scientific progress into improved patient outcomes. This executive synthesis frames those tensions and opportunities, offering pragmatic perspectives to inform near- and mid-term decisions across development, commercialization, and care delivery.

Strategic transition in therapeutic modalities, evidence expectations, and care paradigms driving a new era of innovation and access planning for Hunter syndrome

The therapeutic landscape for Hunter syndrome is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing stakeholder expectations. Gene therapy platforms, leveraging both adeno-associated virus vectors and lentiviral constructs, are advancing from preclinical promise to early clinical proof-of-concept, prompting reconsideration of long-term treatment paradigms previously dominated by intravenous enzyme replacement. At the same time, refinements in enzyme engineering, manufacturing scalability, and alternative dosing strategies are extending the clinical utility of replacement therapies and enabling more patient-centric administration approaches.

Regulators are adapting to the unique evidence needs of rare disease interventions, increasingly emphasizing real-world evidence, patient-reported outcomes, and longer-term safety monitoring. This regulatory evolution is complemented by payer initiatives that demand clearer demonstrations of sustained clinical benefit and value-based contracting options. Additionally, improvements in diagnostic throughput and newborn screening expansion are shifting the population profile at diagnosis toward earlier-stage identification, which amplifies the potential impact of disease-modifying interventions but also places a premium on early access pathways and longitudinal care coordination. Taken together, these shifts are recalibrating R&D prioritization, commercial planning, and health system preparedness across the ecosystem.

Cumulative implications of recent United States tariff measures on supply chains, sourcing strategies, and cost-risk management for Hunter syndrome therapies

Anticipated tariff adjustments in the United States and related policy changes have begun to influence supply chain planning, procurement strategies, and pricing negotiations for imported therapeutic inputs and finished biologics used in Hunter syndrome treatments. Manufacturers reliant on cross-border sourcing for viral vectors, critical raw materials, or finished product distribution face heightened input cost variability and potential lead-time extensions. In response, many developers and contract manufacturers are reassessing geographic diversification of manufacturing capacity and negotiating longer-term supplier agreements to stabilize supply and protect clinical timelines.

Payers and specialty pharmacies are also recalibrating formulary processes to account for potential cost pass-throughs and logistics risk. Procurement teams are increasingly requesting scenario analyses and contract clauses that address tariff-induced cost volatility, while health systems are prioritizing resilience in infusion and home-administration models to limit disruption to patients. Importantly, ongoing dialogue between manufacturers, regulators, and trade advisors is enabling mitigation measures-such as tariff carve-outs for essential biologics, tariff reclassification petitions, or domestic content strategies-to minimize patient impact. These developments underscore the importance of embedding trade policy sensitivity into commercial planning and contingency frameworks for rare disease therapeutics.

In-depth segmentation-driven intelligence revealing how therapeutic modality, administration route, age cohorts, and care settings shape clinical and commercial strategies

A nuanced segmentation framework clarifies how clinical strategies, commercial models, and care delivery must be tailored across distinct therapeutic and patient contexts. Based on treatment type, the landscape encompasses enzyme replacement therapy, gene therapy, hematopoietic stem cell transplant, and supportive therapy; within enzyme replacement therapy, products such as idursulfase and its biosimilar or next-generation analogs define divergent clinical profiles and manufacturing footprints, while gene therapy splits across adeno-associated virus vector and lentiviral vector approaches with different safety, durability, and production considerations. Hematopoietic stem cell transplant pathways involve both allogeneic and autologous approaches, each with disparate graft-versus-host disease risks and infrastructure requirements. Supportive therapy remains critical and is typified by nutritional support, pain management, physical therapy, and respiratory support that collectively underpin quality-of-life interventions.

Differences in route of administration further stratify operational and adherence considerations, with intravenous delivery dominating current enzyme replacement paradigms, oral formulations emerging as patient-preferred adjuncts or supportive regimens where feasible, and subcutaneous approaches offering potential for decentralized care and reduced infusion burden. Patient age group segmentation drives clinical prioritization and outcomes expectations: adult populations-spanning young adult, middle aged, and senior cohorts-exhibit distinct comorbidity profiles and treatment tolerability compared with pediatric patients, who include adolescents, children, infants, and toddlers and who often derive the greatest long-term benefit from early intervention. Finally, end-user settings shape access and care models, whether therapy is administered in ambulatory surgical centers, via home infusion services, in hospital settings, or within specialty clinics focused on multidisciplinary rare disease care. These segmentation lenses must inform clinical trial design, reimbursement strategies, manufacturing scale, and channel selection to ensure therapies align with patient needs and health system capabilities.

Regional strategic differentials and operational levers that determine regulatory pathways, access models, and manufacturing priorities across key global markets

Regional dynamics exert a strong influence on regulatory pathways, reimbursement environment, manufacturing siting, and patient access models. In the Americas, structural strength in rare disease care networks, established specialty pharmacy channels, and concentrated payer negotiation processes create both opportunities and constraints for novel therapies, with particular emphasis on value demonstration and managed entry agreements. Meanwhile, Europe, the Middle East & Africa presents a heterogeneous regulatory and health financing landscape where centralized approvals coexist with country-specific pricing and access mechanisms, necessitating tailored evidence packages and differentiated launch sequencing. Diverse infrastructure capabilities across the region also impact the feasibility of complex administration routes and advanced therapy logistics.

Across the Asia-Pacific region, accelerating investment in advanced manufacturing, expanding newborn screening programs, and evolving regulatory frameworks are enabling faster adoption of innovative modalities, although variability in commercial reimbursement systems and healthcare delivery capacity requires adaptive commercialization models. Supply chain resilience and localized clinical trial capacity are additional considerations that vary by sub-region, influencing decisions on where to site manufacturing and how to deploy early access initiatives. In sum, regional variation demands segmented go-to-market strategies that align clinical value propositions with regulatory expectations, payer priorities, and operational realities across these distinct geographies.

Competitive advantage analysis emphasizing platform differentiation, strategic partnerships, and real-world service models that drive adoption of Hunter syndrome therapies

Competitive dynamics among companies active in Hunter syndrome therapeutics are shaped more by platform differentiation, clinical evidence depth, and supply chain resilience than by simple product lineage. Organizations advancing enzyme replacement candidates are prioritizing improvements in dosing frequency, immunogenicity profiles, and manufacturing economies to preserve relevance amid the rise of gene-based interventions. Developers of gene therapies are investing heavily in vector optimization, dose-range finding, and longitudinal safety surveillance to address concerns about durability and off-target effects, while also building specialized manufacturing capacity to support complex production requirements.

Strategic partnerships and alliances are increasingly prevalent, with biotechnology firms collaborating with contract manufacturers, academic institutions, and clinical networks to accelerate development timelines and broaden access. Commercial playbooks emphasize early engagement with payers, evidence-to-value roadmaps, and innovative contracting approaches that de-risk adoption for health systems. Additionally, companies investing in patient support infrastructure-covering home infusion capabilities, caregiver education, and adherence programs-are better positioned to mitigate real-world access barriers. Overall, competitive advantage accrues to organizations that can align scientific differentiation with pragmatic delivery models and payer-aligned evidence generation.

Actionable strategic priorities for developers and stakeholders to accelerate clinical impact, secure payer acceptance, and fortify supply chain resilience in rare disease care

Industry leaders should adopt an integrated strategic approach that aligns scientific innovation with pragmatic commercialization and patient-centric access models. First, prioritize investment in platform technologies that demonstrably improve CNS penetration, durability, or safety to address the highest unmet clinical needs and create defensible differentiation. Second, develop manufacturing strategies that balance in-house capabilities and strategic outsourcing, incorporating geographic diversification to mitigate tariff and supply chain exposure while ensuring continuity for clinical programs and commercial supply.

Third, engage payers and health technology assessment bodies early to co-design evidence generation plans that incorporate meaningful patient-reported outcomes and real-world data collection, thereby accelerating reimbursement negotiations and managed entry agreements. Fourth, expand patient support services to include decentralized administration options, caregiver education, and adherence support, which will enhance patient experience and reduce systems-level burden. Finally, pursue collaborative alliances across academic centers, advocacy groups, and service providers to leverage shared expertise, optimize trial enrollment, and scale care pathways efficiently. Executing these priorities will require cross-functional governance, adaptive risk management, and a sustained focus on measurable patient outcomes.

Robust multi-method research approach combining expert primary interviews, systematic literature synthesis, and multi-stakeholder validation to support actionable insights

The analysis underpinning this executive summary is grounded in a multi-method research approach that synthesizes primary stakeholder input with rigorous secondary evidence review and quantitative triangulation. Primary research comprised interviews with clinicians specializing in metabolic and pediatric neurology, health system pharmacists, supply chain and manufacturing specialists, and patient advocacy representatives to capture frontline operational challenges and unmet needs. Secondary research included a systematic examination of peer-reviewed clinical literature, regulatory guidance documents, and public filings related to therapeutic modalities, safety signals, and trial endpoints.

Data synthesis involved cross-validation of clinical trends with manufacturing and commercial intelligence to identify convergent themes and potential inflection points. Quality assurance measures included expert panel validation, consensus reconciliation of divergent perspectives, and scenario testing to assess the robustness of conclusions under different policy and supply chain conditions. Ethical considerations and patient privacy protections guided all primary data collection efforts. This layered methodology ensures that the insights presented are actionable, evidence-based, and reflective of multiple stakeholder perspectives across the development-to-delivery continuum.

Synthesis of strategic imperatives and collaborative pathways required to translate scientific advances into durable clinical benefits and equitable patient access

The trajectory of therapeutic innovation for Hunter syndrome points to a more pluralistic treatment environment in which enzyme replacement, gene therapy, curative-intent transplant approaches, and comprehensive supportive care will coexist. Success in this environment depends on aligning scientific performance with operational feasibility and payer-recognized value, while remaining responsive to patient and caregiver priorities. Early diagnosis and timely therapeutic intervention will amplify clinical benefits, underscoring the need for continued investment in screening, multidisciplinary care models, and longitudinal outcome measurement.

Stakeholders that proactively integrate supply chain resilience, evidence generation that reflects real-world effectiveness, and patient-centered service delivery will be best positioned to translate therapeutic advances into durable clinical and commercial outcomes. As the field evolves, sustained collaboration across industry, clinical networks, payers, and patient communities will be essential to overcoming logistical and reimbursement barriers and to delivering meaningful improvements in quality of life for affected individuals and families.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hunter Syndrome Treatment Market, by Treatment Type

  • 8.1. Enzyme Replacement Therapy
    • 8.1.1. Idursulfase
    • 8.1.2. Idursulfase Beta
  • 8.2. Gene Therapy
    • 8.2.1. Adeno Associated Virus Vector
    • 8.2.2. Lentiviral Vector
  • 8.3. Hematopoietic Stem Cell Transplant
    • 8.3.1. Allogeneic Transplant
    • 8.3.2. Autologous Transplant
  • 8.4. Supportive Therapy
    • 8.4.1. Nutritional Support
    • 8.4.2. Pain Management
    • 8.4.3. Physical Therapy
    • 8.4.4. Respiratory Support

9. Hunter Syndrome Treatment Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Hunter Syndrome Treatment Market, by Patient Age Group

  • 10.1. Adult
    • 10.1.1. Middle Aged
    • 10.1.2. Senior
    • 10.1.3. Young Adult
  • 10.2. Pediatric
    • 10.2.1. Adolescent
    • 10.2.2. Child
    • 10.2.3. Infant
    • 10.2.4. Toddler

11. Hunter Syndrome Treatment Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Home Infusion
  • 11.3. Hospital
  • 11.4. Specialty Clinic

12. Hunter Syndrome Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Hunter Syndrome Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Hunter Syndrome Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Hunter Syndrome Treatment Market

16. China Hunter Syndrome Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott
  • 17.6. ArmaGen, Inc.
  • 17.7. Bayer AG
  • 17.8. BioMarin Pharmaceutical Inc.
  • 17.9. Denali Therapeutics
  • 17.10. F. Hoffmann-La Roche Ltd
  • 17.11. Green Cross Corporation
  • 17.12. GSK Plc.
  • 17.13. Inventiva S.A.
  • 17.14. JCR Pharmaceuticals Co., Ltd.
  • 17.15. Johnson & Johnson Services, Inc.
  • 17.16. Medtronic
  • 17.17. Regenxbio Inc.
  • 17.18. Sangamo Therapeutics, Inc.
  • 17.19. Stryker Corporation
  • 17.20. Takeda Pharmaceutical Company Limited
  • 17.21. Zimmer Biomet

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY IDURSULFASE BETA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADENO ASSOCIATED VIRUS VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY LENTIVIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ALLOGENEIC TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AUTOLOGOUS TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY RESPIRATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY MIDDLE AGED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY YOUNG ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TODDLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 208. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 209. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 212. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 213. GCC HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 241. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 245. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 246. G7 HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 252. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 256. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 257. NATO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY ADULT, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)